Mats Remberger1, Berit Sundberg. 1. Department of Clinical Immunology, Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden. mats.remberger@labmed.ki.se <mats.remberger@labmed.ki.se >
Abstract
BACKGROUND AND OBJECTIVES: The role of serum concentrations of rabbit antithymoglobulin (ATG) in the development of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) with unrelated donors is unknown. DESIGN AND METHODS: We determined the serum concentration of rabbit immunoglobulin-G (IgG) using an enzyme linked immunosorbent assay in 61 patients after unrelated donor HSCT. The doses of ATG ranged between 4 and 10 mg/kg. The conditioning consisted mainly of cyclophosphamide and total body irradiation or busulfan. Most patients received GVHD prophylaxis with cyclosporine and methotrexate. RESULTS: The rabbit IgG levels varied widely in each dose group. The levels of rabbit IgG gradually declined and could still be detected up to five weeks after HSCT. We found a correlation between the grade of acute GVHD and the concentration of rabbit IgG in serum before the transplantation (p=0.017). Patients with serum levels of rabbit IgG >70 mg/mL before HSCT ran a very low risk of developing acute GVHD grades II-IV, as compared to those with levels <70 mg/mL (11% vs. 48%, p=0.006). INTERPRETATION AND CONCLUSIONS: The measurement of rabbit IgG levels in patients receiving ATG as prophylaxis against GVHD after HSCT may be of value in lowering the risk of severe GVHD.
BACKGROUND AND OBJECTIVES: The role of serum concentrations of rabbit antithymoglobulin (ATG) in the development of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) with unrelated donors is unknown. DESIGN AND METHODS: We determined the serum concentration of rabbit immunoglobulin-G (IgG) using an enzyme linked immunosorbent assay in 61 patients after unrelated donor HSCT. The doses of ATG ranged between 4 and 10 mg/kg. The conditioning consisted mainly of cyclophosphamide and total body irradiation or busulfan. Most patients received GVHD prophylaxis with cyclosporine and methotrexate. RESULTS: The rabbit IgG levels varied widely in each dose group. The levels of rabbit IgG gradually declined and could still be detected up to five weeks after HSCT. We found a correlation between the grade of acute GVHD and the concentration of rabbit IgG in serum before the transplantation (p=0.017). Patients with serum levels of rabbit IgG >70 mg/mL before HSCT ran a very low risk of developing acute GVHD grades II-IV, as compared to those with levels <70 mg/mL (11% vs. 48%, p=0.006). INTERPRETATION AND CONCLUSIONS: The measurement of rabbit IgG levels in patients receiving ATG as prophylaxis against GVHD after HSCT may be of value in lowering the risk of severe GVHD.
Authors: Dorothea Evers; Jaap Jan Zwaginga; Janneke Tijmensen; Rutger A Middelburg; Masja de Haas; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom Journal: Haematologica Date: 2016-09-15 Impact factor: 9.941
Authors: Qaiser Bashir; Mark F Munsell; Sergio Giralt; Leandro de Padua Silva; Manish Sharma; Daniel Couriel; Alexandre Chiattone; Uday Popat; Muzaffar H Qazilbash; Marcelo Fernandez-Vina; Richard E Champlin; Marcos J de Lima Journal: Leuk Lymphoma Date: 2011-12-05
Authors: Sandra K Call; Kimberly A Kasow; Raymond Barfield; Renee Madden; Wing Leung; Edwin Horwitz; Paul Woodard; John C Panetta; Sharyn Baker; Rupert Handgretinger; John Rodman; Gregory A Hale Journal: Biol Blood Marrow Transplant Date: 2009-02 Impact factor: 5.742